射频消融联合肝动脉化疗栓塞对原发性肝癌的疗效分析  

Effect of RFA combined with TACE for Primary Hepatocellular Carcinoma

作　　者：宋莉[1] 佟小强[1] 王健[1] 杨敏[1] 吕永兴[1] 邹英华[1] 

机构地区：[1]北京大学第一医院介入血管外科,北京100034

出　　处：《当代医学》2009年第23期404-406,共3页Contemporary Medicine

摘　　要：目的评价射频消融联合肝动脉化疗栓塞对原发性肝癌的治疗效果,总结治疗过程中的经验教训。方法对81例原发性肝癌患者共114个病灶进行射频消融治疗联合肝动脉化疗栓塞。术前术后患者均进行增强CT扫描,随访期间患者每2～3个月进行一次CT扫描。结果平均随访30±10.9(17～49)个月。至观察终点1、2、3年生存率分别为96.6%、93.2%和68.2%。中位生存期为34个月(95%CI:18～49月)。全组死亡24例,目前存活57例,其中35例处于疾病控制期。结论射频消融结合TACE治疗可有效治疗原发性肝癌,可延长患者的生存期。Objectives： To investigate the efficacy and safety of RFA in treating primary hepatocellular carcinoma. Methods： Eighty-one patients with total 114 tumors were treated with radiofrequency ablation combined with TACE. Preoperative and postprocedural CT scans were taken in all patients. During follow-up patients underwent enhanced CT in every 2-3 month interval. Results： Median following-up duration was 30 ± 10.9months （17-49）. The median survival time was 34 monthes （95%CI： 18-49 mo.）.1-,2and 3-year survival rate was 96.6%, 93.2% and 68.2%, respectively. 57 patients who were still alive when following-up ended. Conclusions： Radiofrequency ablation combined with TACE is effective and reliable in treating primary hepatocellular carcinoma. It may prolong the survival of the patients.

关 键 词：射频消融 肝脏恶性肿瘤 

分 类 号：R735.7[医药卫生—肿瘤]